Elevated prolactin levels in bronchogenic carcinoma.
The frequency and significance of hyperprolactinemia was studied in 21 consecutive, untreated male patients with bronchogenic carcinoma. Seven patients (33%) were found to have elevated serum prolactin (hPRL) levels. No correlation was demonstrated between increased hPRL levels, tissue histology, or tumor burden. L-dopa suppression and/or TRH stimulation tests were obtained in three untreated patients with hyperprolactinemia. The results of these tests were considered normal suggesting hypothalamic control.
D000230:Adenocarcinoma / Q000097:blood; D000328:Adult; D000368:Aged; D002283:Carcinoma, Bronchogenic / Q000097:blood*; D018288:Carcinoma, Small Cell / Q000097:blood; D002294:Carcinoma, Squamous Cell / Q000097:blood; D006729:Hormones, Ectopic / Q000097:blood; D006801:Humans; D007980:Levodopa / Q000494:pharmacology; D008175:Lung Neoplasms / Q000097:blood*; D008297:Male; D008875:Middle Aged; D011388:Prolactin / Q000097:blood*; D013973:Thyrotropin-Releasing Hormone / Q000494:pharmacology
D006729:Hormones, Ectopic; D007980:Levodopa; D013973:Thyrotropin-Releasing Hormone; D011388:Prolactin